Treatment of lymph node-positive prostate cancer: Teaching old dogmas new tricks

European Urology

Volumn 65, Issue 1, 2014, Pages 26-28

  Briganti, Alberto ^a   Passoni, Niccolò M ^a   Abdollah, Firas ^a   Nini, Alessandro ^a   Montorsi, Francesco ^a   Karnes, R Jeffrey ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; CANCER CELL; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; EDITORIAL; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; NONHUMAN; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURGICAL TECHNIQUE; SURVIVAL PREDICTION; SYSTEMIC DISEASE; TUMOR CELL; MALE; PATHOLOGY; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84888821665     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.07.003     Document Type: Editorial

References (10)

1. M.G. Achen, and S.A. Stacker Molecular control of lymphatic metastasis Ann N Y Acad Sci 1131 2008 225 234
2. S. Hirakawa, L.F. Brown, S. Kodama, K. Paavonen, K. Alitalo, and M. Detmar VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites Blood 109 2007 1010 1017
3. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564
4. Z. Barekati, R. Radpour, and Q. Lu Methylation signature of lymph node metastases in breast cancer patients BMC Cancer 12 2012 244
5. J.A. Aguirre-Ghiso Models, mechanisms and clinical evidence for cancer dormancy Nat Rev Cancer 7 2007 834 846
6. A. Briganti, J.R. Karnes, and L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
7. A. Touijer, C.R. Mazzola, D.D. Sjoberg, P.T. Scardino, and J.A. Eastham Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy Eur Urol 65 2014 20 25
8. M.E. Shukla, C.A. Reddy, and K.L. Stephans Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy [abstract] J Clin Oncol 30 Suppl 2012 195
9. E.M. Messing, J. Manola, J. Yao Eastern Cooperative Oncology Group study EST 3886 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
10. F. Abdollah, N. Suardi, and A. Gallina Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center Ann Oncol 24 2013 1459 1466